Pitobrutinib Chinese instructions

Pitobrutinib (Jaypirca) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Pitotinib tablets may help reduce the number of CLL, SLL, and MCL, and in the case of MCL, it may eliminate the cancer. It can help treat cancer in patients who have been treated with ibrutinib, acalabrutinib, or zanubrutinib (covalent BTK inhibitors) because it works differently than these anticancer drugs.

Usage and Dosage: Pitoplutinib Titinib Treatment Usual adult dosage for CLL, SLL and MCL: 200 mg orally daily
Duration of treatment: until disease progression or unacceptable toxicity. These indications are approved on an accelerated basis based on response rate. Continued approval for this indication may be contingent on verification and description of clinical benefit in confirmatory trials.

Side effects:

Common side effects of pibbrutinib may include bruising, tiredness, diarrhea, swelling, muscle, joint pain, bone pain, fever, chills, cough, chest pain, and shortness of breath.

Serious pibbrutinib side effects: Get emergency medical help if you have signs of an allergic reaction, such as hives, difficulty breathing, or swelling of your face, lips, tongue, or throat.

Other serious pibbrutinib side effects. Contact your doctor right away if you have: chest pressure, rapid heartbeat or palpitations, chest fluttering, shortness of breath; signs of infection—fever, chills, sore throat , body aches, unusual tiredness, loss of appetite, bruising or bleeding; internal bleeding - weakness, dizziness; pink or brown urine; abnormal vaginal bleeding; bloody or tarry stools, coughing up blood or vomiting that looks like coffee grounds; or low blood cell count - Fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, dizziness, or shortness of breath.

If you experience certain side effects, your cancer treatment may be delayed or permanently stopped.

Things to note:

Infection. Serious and fatal infections caused by bacteria, viruses, or fungi have occurred with pitobrutinib, of which 24% were grade 3 or higher; opportunistic infections, such as those caused by Pneumocystis jiroveci pneumonia, have also occurred. For those at high risk, preventive measures such as vaccinations and antibiotics should be considered.

Bleeding. Serious and fatal bleeding events have also occurred with pitobrutinib. Monitor for any signs of bleeding and treat appropriately.

Low blood cell count. Lower than normal blood cell counts may occur, including low neutrophil, platelet, or red blood cell counts. Your healthcare provider will monitor your blood counts regularly throughout treatment.

Arrhythmias. Arrhythmias, including atrial fibrillation and atrial flutter, may occur, as may second primary cancers, including skin cancer. Wear sun protection when going out.

Fetal hazard. This medicine can cause fetal harm. Women of childbearing age should take effective contraceptive measures. It's unclear whether this drug is safe and effective in children.

Storage: Store tablets at room temperature 68°F to 77°F (20°C to 25°C). The tablets come in a bottle with a child-proof cap. Keep all medicines out of the reach of children and pets.

xa0

Reference: https://www.drugs.com/pirtobrutinib.html